ENGIpore

pre-formed bone substitute

ENGIpore-pre-formed bone substitute

Micro, macro and interconnected porosity

This biomaterial has a unique, controlled micro and macro porosity along with an effective structure that supports rapid bone ingrowth and formation.

Its unique structure gives ENGIpore a porosity of almost 90%, and this guarantees an easy access of cells, biological fluids, and attracting the correct molecules throughout the bone substitute.

Rapid osteointegration

Once applied in situ, ENGIpore rapidly absorbs all bio-active proteins, growth factors and bone precursor cells contained in the physiological fluids. This encourages and begins the biological cascade leading to effective bone regeneration.

ENGIpore may be used for various surgical procedures:

    . Multi-walled bone lesions with or without membrane

    . Empty extraction sockets

    . Periodontal bone lesions

ENGIpore may be mixed with autologous bone, blood, antibiotics and saline solution, bone marrow concentrate and growth factors.

ENGIpore is available with the following codes:

Chips

code
description
q.ty per Package
PFS015005-60-00
Chip 0,5-1,0 mm - 0,5 g
1
PFS015105-60-00
Chip 0,5-1,0 mm
2 Single-doses 0,5 g/cad
PFS015005-52-00

Blocks

code
description
q.ty per Package
PFS015005-01-00
10x10x10 mm block
1
PFS015005-12-00
10x5x5 mm block
1
  1. Barbanti Brodano, G., Mazzoni, E., Tognon, M., Griffoni, C. & Manfrini, M. Human mesenchymal stem cells and biomaterials interaction: a promising synergy to improve spine fusion. Eur Spine J 21 Suppl 1, S3–9 (2012).
  2. De Girolamo, L. et al. Role of autologous rabbit adipose-derived stem cells in the early phases of the repairing process of critical bone defects. J. Orthop. Res. 29, 100–108 (2011).
  3. Güven, S. et al. Engineering of large osteogenic grafts with rapid engraftment capacity using mesenchymal and endothelial progenitors from human adipose tissue. Biomaterials 32, 5801–5809 (2011).
  4. Manfrini, M. et al. Mesenchymal stem cells from patients to assay bone graft substitutes. J. Cell. Physiol. 228, 1229–1237 (2013).
  5. Mangano, C. et al. Maxillary sinus augmentation using an engineered porous hydroxyapatite: a clinical, histological, and transmission electron microscopy study in man. J Oral Implantol 32, 122–131 (2006).
  6. Paderni, S., Terzi, S. & Amendola, L. Major bone defect treatment with an osteoconductive bone substitute. Chir Organi Mov 93, 89–96 (2009).
  7. Pettinicchio, M. et al. Histologic and histomorphometric results of three bone graft substitutes after sinus augmentation in humans. Clin Oral Investig 16, 45–53 (2012).
  8. Scala, M. et al. Clinical applications of autologous cryoplatelet gel for the reconstruction of the maxillary sinus. A new approach for the treatment of chronic oro-sinusal fistula. In Vivo 21, 541–547 (2007).
  9. Timmins, N. E. et al. Three-dimensional cell culture and tissue engineering in a T-CUP (tissue culture under perfusion). Tissue Eng. 13, 2021–2028 (2007).
ENGIpore